Real world Effectiveness of Tixagevimab-cilgavimab for COVID-19 Prevention in Thai Solid Organ Transplant Recipients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220801004

Enrollment

100

Registered

2022-08-01

Start date

2022-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult solid organ transplant recipients Monoclonal antibody kidney liver heart transplant

Interventions

Adult solid organ transplant recipients who have inadequate vaccine responses will be enrolled for tixagevimab 150 mg /cilgavimab 150 mg intramuscular injection for one dose ,Adult solid organ transpl

Experimental Biological/Vaccine,Placebo Comparator Biological/Vaccine

Tixa/cilga,Placebo

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: All adult (>15 years old) SOT recipients within 6 months transplant, suspected having inadequate vaccine responses

Exclusion criteria

Exclusion criteria: Unwilling to participate, allergic to tixa/cilga

Design outcomes

Primary

Measure	Time frame
COVID-19 infection 6 months COVID-19 diagnosis confirmed by RT-PCR	—

Secondary

Measure	Time frame
Safety 6 months Side effect: allergic reaction	—

Countries

Thailand

Contacts

Public ContactJackrapong Bruminhent

Faculty of Medicine Ramathibodi Hospital, Mahidol University

jackrapong.brm@mahidol.ac.th022011581

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026